NYSE - Nasdaq Real Time Price USD

Haemonetics Corporation (HAE)

Compare
75.06 -0.55 (-0.73%)
As of 2:44 PM EDT. Market Open.
Loading Chart for HAE
DELL
  • Previous Close 75.61
  • Open 76.34
  • Bid 74.92 x 800
  • Ask 75.10 x 1000
  • Day's Range 74.07 - 76.60
  • 52 Week Range 70.74 - 97.97
  • Volume 266,440
  • Avg. Volume 592,479
  • Market Cap (intraday) 3.841B
  • Beta (5Y Monthly) 0.30
  • PE Ratio (TTM) 33.66
  • EPS (TTM) 2.23
  • Earnings Date Oct 31, 2024 - Nov 4, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 109.80

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

www.haemonetics.com

3,657

Full Time Employees

March 30

Fiscal Year Ends

Recent News: HAE

View More

Performance Overview: HAE

Trailing total returns as of 9/19/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

HAE
12.22%
S&P 500
20.05%

1-Year Return

HAE
17.65%
S&P 500
28.58%

3-Year Return

HAE
6.89%
S&P 500
29.18%

5-Year Return

HAE
41.26%
S&P 500
90.45%

Compare To: HAE

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: HAE

View More

Valuation Measures

Annual
As of 9/18/2024
  • Market Cap

    3.87B

  • Enterprise Value

    4.75B

  • Trailing P/E

    33.91

  • Forward P/E

    14.68

  • PEG Ratio (5yr expected)

    1.22

  • Price/Sales (ttm)

    2.92

  • Price/Book (mrq)

    4.27

  • Enterprise Value/Revenue

    3.56

  • Enterprise Value/EBITDA

    18.67

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    8.61%

  • Return on Assets (ttm)

    6.09%

  • Return on Equity (ttm)

    12.98%

  • Revenue (ttm)

    1.33B

  • Net Income Avi to Common (ttm)

    114.89M

  • Diluted EPS (ttm)

    2.23

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    346.06M

  • Total Debt/Equity (mrq)

    143.23%

  • Levered Free Cash Flow (ttm)

    106.46M

Research Analysis: HAE

View More

Company Insights: HAE

Research Reports: HAE

View More

People Also Watch